Neurogene Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its current pipeline centers on gene therapy programs designed to address severe disorders such as Rett syndrome and CLN5 Batten disease, with candidates that use adeno-associated virus delivery and proprietary transgene regulation technology to control gene expression in the central nervous system. Neurogene’s work is aimed at treating conditions with significant unmet medical need, where conventional approaches have limited impact on the underlying cause of disease. The company also operates gene therapy manufacturing capabilities to support clinical development and production of its programs. Headquartered in New York, Neurogene Inc. is part of the broader biotechnology and rare-disease therapeutics market, where it contributes to the advancement of precision genetic medicine for devastating neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Rachel L. McMinn Ph.D.
- Employees
- 131
- Headquarters
- New York, NY, United States
- Website
- www.neurogene.com